ABSTRACT
Doxepin, a Class-I Biopharmaceutics Drug Disposition Classification System (BDDCS) drug, exhibits poor bioavailability due to extensive first-pass metabolism. This research focuses on enhancing the delivery of doxepin by formulating nanostructured lipid carriers (NLCs) through the utilization of the Box-Behnken Design methodology. These optimized NLCs are intended for intranasal administration, with the ultimate goal of improving nose-to-brain drug delivery. NLCs were formulated using a high-speed homogenization technique. The optimized batch had a small particle size (75.80 ± 5.48 nm, PDI = 0.286), high entrapment efficiency (94.10 ± 0.16%), and sustained ex vivo release (82.25 ± 4.61% at 24 h). Characterization studies confirmed the conversion of doxepin from a crystalline to an amorphous state with uniform distribution in the lipid matrix. In vivo pharmacokinetic studies in rats showed significantly higher doxepin concentration in the brain tissue (Cmax = 16.77 µg/g, tmax = 30 min) after intranasal administration compared to intravenous administration (Cmax = 2.53 µg/g, tmax = 6 h). High-drug targeting efficiency (DTE = 284.3%) and direct transport percentage (DTP = 64.8%) suggested direct penetration of NLCs in the brain via olfactory and trigeminal pathways. In conclusion, the study highlights the potential of NLCs to improve the bioavailability of doxepin through nose-to-brain delivery and thereby potentially enable the treatment of neurological disorders.
Subject(s)
Administration, Intranasal , Biological Availability , Brain , Doxepin , Drug Carriers , Lipids , Nanostructures , Animals , Doxepin/pharmacokinetics , Doxepin/administration & dosage , Brain/metabolism , Lipids/chemistry , Drug Carriers/chemistry , Rats , Male , Nanostructures/chemistry , Particle Size , Drug Delivery Systems/methods , Rats, Sprague-Dawley , Drug Liberation , Biopharmaceutics/methods , Nasal Mucosa/metabolismABSTRACT
Receptor occupancy is an indicator of antipsychotic efficacy and safety. It is desirable to simultaneously determine the occupancy of multiple brain receptors as an indicator of the efficacy and central side effects of antipsychotics because many of these drugs have binding affinities for various receptors, such as dopamine 2 (D2), histamine 1 (H1), and muscarinic acetylcholine (mACh) receptors. The purpose of this study was to develop a method for the simultaneous measurement of multiple receptor occupancies in the brain by the simultaneous quantification of unlabeled tracer levels using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Rats were pre-administered with a vehicle, displacer, or olanzapine, and mixed solutions of raclopride, doxepin, and 3-quinuclidinyl benzilate (3-QNB) were administered (3, 10, and 30 µg/kg). The brain tissue and plasma tracer concentrations were quantified 45 min later using LC-MS/MS, and the binding potential was calculated. The highest binding potential was observed at 3 µg/kg raclopride, 10 µg/kg doxepin, and 30 µg/kg 3-QNB. Tracer-specific binding at these optimal tracer doses in the cerebral cortex was markedly reduced by pre-administration of displacers. D2, H1, and mACh receptor occupancy by olanzapine increased in a dose-dependent manner, reaching 70-95%, 19-43%, and 12-45%, respectively, at an olanzapine dose range of 3-10 mg/kg. These results suggest that simultaneous determination of in vivo D2, H1, and mACh receptor occupancy is possible using LC-MS/MS.
Subject(s)
Antipsychotic Agents , Olanzapine , Rats, Sprague-Dawley , Receptors, Dopamine D2 , Receptors, Histamine H1 , Receptors, Muscarinic , Tandem Mass Spectrometry , Animals , Tandem Mass Spectrometry/methods , Rats , Male , Antipsychotic Agents/administration & dosage , Chromatography, Liquid/methods , Receptors, Dopamine D2/metabolism , Receptors, Muscarinic/metabolism , Receptors, Muscarinic/drug effects , Receptors, Histamine H1/metabolism , Olanzapine/pharmacokinetics , Olanzapine/administration & dosage , Brain/metabolism , Brain/drug effects , Benzodiazepines/analysis , Benzodiazepines/metabolism , Benzodiazepines/pharmacokinetics , Raclopride/metabolism , Doxepin/pharmacokinetics , Quinuclidinyl Benzilate/metabolism , Dose-Response Relationship, DrugABSTRACT
Neste artigo é exposto sucintamente aspectos do metabolismo dos antidepressivos tricíclicos (desmetilaçao e hipdroxilaçao) que devem ser levados em conta na interpretaçao das dosagens plasmáticas e efeitos clínicos destes medicamentos